Peter Hau

Summary

Affiliation: University of Regensburg
Country: Germany

Publications

  1. ncbi request reprint Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin
    Peter Hau
    Department of Neurology, University of Regensburg, Germany
    Anticancer Res 22:577-83. 2002
  2. ncbi request reprint Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP) [corrected]
    Peter Hau
    Department of Neurology, University of Regensburg, Regensburg, Germany
    J Invest Dermatol 119:562-9. 2002
  3. doi request reprint CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors
    Dagmar Beier
    Laboratory of Neurooncology, Department of Neurology, University of Regensburg, Medical School, Regensburg, Germany
    Brain Pathol 18:370-7. 2008
  4. doi request reprint Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05)
    Oliver Grauer
    Department of Neurology, University Medical Center Regensburg, Universitatsstrasse 84, 93053, Regensburg, Germany
    J Neurooncol 104:801-9. 2011
  5. doi request reprint Temozolomide preferentially depletes cancer stem cells in glioblastoma
    Dagmar Beier
    Department of Neurology, University of Regensburg, Medical School, Regensburg, Germany
    Cancer Res 68:5706-15. 2008
  6. ncbi request reprint Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques
    Piotr Jachimczak
    Antisense Pharma GmbH, Regensburg, Germany
    Int J Cancer 113:88-92. 2005
  7. pmc RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study
    Christoph P Beier
    Department of Neurology, University of Regensburg, Universitatsstrasse 84, 93053 Regensburg, Germany
    BMC Cancer 9:308. 2009
  8. doi request reprint Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series
    Martin Glas
    Department of Neurology, University of Regensburg, Regensburg, Germany
    Oncology 72:302-7. 2007
  9. ncbi request reprint Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies
    Peter Hau
    Department of Neurology, University of Regensburg, Germany
    Oligonucleotides 17:201-12. 2007
  10. doi request reprint Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model
    Sridhar R Chirasani
    Department of Neurology, University Medical Centre of Regensburg, Regensburg, Germany
    Int J Cancer 132:843-53. 2013

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin
    Peter Hau
    Department of Neurology, University of Regensburg, Germany
    Anticancer Res 22:577-83. 2002
    ..Elevated levels of melanoma-inhibiting activity (MIA/CD-RAP) have also been measured in a subgroup of patients with advanced stage breast carcinomas...
  2. ncbi request reprint Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP) [corrected]
    Peter Hau
    Department of Neurology, University of Regensburg, Regensburg, Germany
    J Invest Dermatol 119:562-9. 2002
    ..Whereas the biologic function of melanoma-inhibiting activity (splice) is not clear yet, it might provide a relevant diagnostic and therapeutic tool for malignant melanomas...
  3. doi request reprint CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors
    Dagmar Beier
    Laboratory of Neurooncology, Department of Neurology, University of Regensburg, Medical School, Regensburg, Germany
    Brain Pathol 18:370-7. 2008
    ..The presence or absence of CD133(+) CSC might explain the crucial biological difference between WHO grade III and IV oligodendroglial tumors...
  4. doi request reprint Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05)
    Oliver Grauer
    Department of Neurology, University Medical Center Regensburg, Universitatsstrasse 84, 93053, Regensburg, Germany
    J Neurooncol 104:801-9. 2011
    ..In conclusion, 13-cRA addition to TMZ in a neoadjuvant setting showed acceptable toxicity, but did not yield an advantage in PFS in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection...
  5. doi request reprint Temozolomide preferentially depletes cancer stem cells in glioblastoma
    Dagmar Beier
    Department of Neurology, University of Regensburg, Medical School, Regensburg, Germany
    Cancer Res 68:5706-15. 2008
    ..Accordingly, our data strongly suggest that optimized temozolomide-based chemotherapeutic protocols might substantially improve the elimination of GBM stem cells and consequently prolong the survival of patients...
  6. ncbi request reprint Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques
    Piotr Jachimczak
    Antisense Pharma GmbH, Regensburg, Germany
    Int J Cancer 113:88-92. 2005
    ..Antagonization of MIA activity using antisense techniques may represent a novel therapeutic strategy for treatment of malignant melanomas...
  7. pmc RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study
    Christoph P Beier
    Department of Neurology, University of Regensburg, Universitatsstrasse 84, 93053 Regensburg, Germany
    BMC Cancer 9:308. 2009
    ..Although Temozolomide is effective against glioblastoma, the prognosis remains dismal and new regimens with synergistic activity are sought for...
  8. doi request reprint Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series
    Martin Glas
    Department of Neurology, University of Regensburg, Regensburg, Germany
    Oncology 72:302-7. 2007
    ..After previous potentially encouraging reports on liposomal pegylated doxorubicin (PEG-DOX) in this setting, PEG-DOX was applied to patients with recurrent malignant glioma in an institutional series...
  9. ncbi request reprint Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies
    Peter Hau
    Department of Neurology, University of Regensburg, Germany
    Oligonucleotides 17:201-12. 2007
    ..These results implicate targeted TGF-beta2-suppression using AP 12009 as a promising novel approach for malignant gliomas and other highly aggressive, TGF-beta-2-overexpressing tumors...
  10. doi request reprint Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model
    Sridhar R Chirasani
    Department of Neurology, University Medical Centre of Regensburg, Regensburg, Germany
    Int J Cancer 132:843-53. 2013
    ..In summary, diclofenac appears as an attractive agent for targeting lactate production and counteracting local immune suppression in malignant gliomas...
  11. pmc Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2
    Fusun Baumann
    Department of Neurology, University of Regensburg, Universitatsstrasse 84, 93053 Regensburg, Germany
    Neuro Oncol 11:368-80. 2009
    ..This novel interaction between lactate metabolism and TGF-beta2 might constitute a crucial mechanism for glioma migration...
  12. ncbi request reprint TGF-β2 signaling in high-grade gliomas
    Peter Hau
    University of Regensburg, Department of Neurology, Universitätsstr 84, 93053 Regensburg, Germany
    Curr Pharm Biotechnol 12:2150-7. 2011
    ..On the basis of these data the currently ongoing phase III study SAPHIRRE was initiated...
  13. ncbi request reprint Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas
    Peter Hau
    Department of Neurology, University of Regensburg, Universitatsstrasse 84, 93053, Regensburg, Germany
    J Neurooncol 77:1-7. 2006
    ..This study was designed to evaluate if TGF-beta1 induces the expression and deposition of Tenascin-C in the extracellular matrix of high-grade gliomas which may be pivotal for the invasion of these tumors into healthy parenchyma...
  14. pmc The cancer stem cell subtype determines immune infiltration of glioblastoma
    Christoph P Beier
    Department of Neurology, RWTH Aachen, Aachen, Germany
    Stem Cells Dev 21:2753-61. 2012
    ..Thus, the molecular subtype of CSCs TGF-beta-dependently contributes to the degree of immune infiltration...
  15. doi request reprint 1H-nuclear magnetic resonance spectroscopy of glioblastoma cancer stem cells
    Paul Ramm
    Institute of Biophysics and Physical Biochemistry, University of Regensburg, Regensburg, Germany
    Stem Cells Dev 20:2189-95. 2011
    ..In conclusion, our exploratory study demonstrates the correlation of specific resonances within (1)H-NMR spectra with stem cell properties and advocates the use of the 1.28 ppm resonance as biomarker for cell death also in CSCs...
  16. doi request reprint Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
    Caecilia Wismeth
    Department of Neurology, University of Regensburg Medical School UKR, Universitatsstrasse 84, 93053, Regensburg, Germany
    J Neurooncol 98:395-405. 2010
    ..Episodes of intracranial pressure were, at least, possibly attributed to EHT but did not cause DLTs. A Phase II trial targeting treatment effects is warranted on the basis of the results raised in this trial...
  17. ncbi request reprint CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
    Dagmar Beier
    Laboratory of Neurooncology, University of Regensburg, Regensburg, Germany
    Cancer Res 67:4010-5. 2007
    ..The remainder stems from previously unknown CD133(-) tumor cells with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo...
  18. ncbi request reprint Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety
    Reimar Schlingensiepen
    Antisense Pharma GmbH, Regensburg, Germany
    Oligonucleotides 15:94-104. 2005
    ..This favorable safety profile proves the suitability of AP 12009 for local administration in brain tumor patients from the point of view of toxicology...
  19. doi request reprint Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides
    Peter Hau
    Department of Neurology, University of Regensburg, Medical School, Regensburg, Germany
    Expert Rev Anticancer Ther 9:1663-74. 2009
    ....
  20. doi request reprint Stem cell metabolic and spectroscopic profiling
    Paul Ramm Sander
    Institute of Biophysics and Physical Biochemistry, University of Regensburg, 93040 Regensburg, Germany
    Trends Biotechnol 31:204-13. 2013
    ....
  21. doi request reprint Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
    Hendrik Pels
    Department of Neurology, Knappschaftskrankenhaus, University of Bochum, In der Schornau 23 25, Bochum, Germany
    J Neurooncol 91:299-305. 2009
    ..Here, the efficacy and toxicity of this regimen without intraventricular treatment was evaluated in PCNSL...
  22. ncbi request reprint Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors
    Sabine Wagner
    Department of Pediatric Oncology, Krankenhaus der Barmherzigen Bruder, Klinik St Hedwig, Steinmetzstrasse 1 3, Regensburg, Germany
    J Neurooncol 86:175-81. 2008
    ..To confirm the effectiveness of this treatment combination and determine its possible toxicity, we conducted a retrospective review of the charts of children who received the therapy...
  23. pmc New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells
    Eva Gottfried
    Department of Hematology and Oncology, University of Regensburg, Regensburg, Germany
    PLoS ONE 8:e66987. 2013
    ..Based on these results, diclofenac holds potential as a clinically applicable MYC and glycolysis inhibitor supporting established tumor therapies. ..
  24. ncbi request reprint Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study
    Caecilia Wismeth
    Department of Neurology, University of Regensburg, Regensburg, Germany
    J Neurooncol 68:79-86. 2004
    ..According to in vitro and in vivo clinical studies, 13-cis retinoic acid (cRA) may be a promising agent for maintenance therapy in these patients...
  25. ncbi request reprint Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma
    Peter Hau
    Klinik und Poliklinik für Neurologie der Universität Regensburg, Regensburg, Germany
    Cancer 100:1199-207. 2004
    ....
  26. ncbi request reprint Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers
    Christian Hafner
    Department of Dermatology, University of Regensburg, Regensburg, Germany
    Clin Chem 50:490-9. 2004
    ..Their role in healthy adult tissues and in human disease is still largely unknown, although diverse roles in carcinogenesis have been postulated...
  27. ncbi request reprint Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma
    Peter Hau
    Klinik und Poliklinik fuer Neurologie der Universitaet Regensburg am Bezirksklinikum, 93053 Regensburg, Germany
    Oncol Rep 12:1355-64. 2004
    ..While a mechanistic relation has not yet been verified, factors such as a high fiber content of the extracellular matrix may explain this observation...
  28. ncbi request reprint Procarbazine--a traditional drug in the treatment of malignant gliomas
    Rainer Goerne
    Division of NeuroOncology, Klinik und Poliklinik für Neurologie der Universität Regensburg am Bezirksklinikum, Universitatsstrasse 84, 93053 Regensburg, Germany
    Curr Med Chem 15:1376-87. 2008
    ..This article summarizes the existing data with the goal to define the role of PCZ/PCV in modern neurooncology...